Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) is set to announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Parties that wish to listen to the company's conference call can do so using this link.
Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.06. The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.30 million. Vistagen Therapeutics had a negative return on equity of 35.12% and a negative net margin of 3,421.85%. During the same quarter in the prior year, the company earned ($0.94) earnings per share. On average, analysts expect Vistagen Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Vistagen Therapeutics Trading Up 1.0 %
VTGN traded up $0.03 on Friday, hitting $3.11. 133,685 shares of the company were exchanged, compared to its average volume of 216,122. The firm has a 50-day moving average price of $3.13 and a two-hundred day moving average price of $3.62. Vistagen Therapeutics has a twelve month low of $2.45 and a twelve month high of $5.86. The company has a market cap of $84.16 million, a price-to-earnings ratio of -2.10 and a beta of 0.78.
Analyst Upgrades and Downgrades
Separately, William Blair raised Vistagen Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th.
View Our Latest Research Report on VTGN
About Vistagen Therapeutics
(
Get Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Featured Articles
Before you consider Vistagen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vistagen Therapeutics wasn't on the list.
While Vistagen Therapeutics currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
